Skip to main content

Table 2 Multivariate analysis for pCR

From: Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

  Intratumoral CD4 Stromal CD4
HR 95% CI P value HR 95% CI P value
Age 0.93 0.853–1.011 0.072 0.9 0.821–0.996 0.024
Dose 1.073 1.005–1.147 0.0073 1.059 0.994–1.13 0.032
HRD 0.92 0.848–1.005 0.053 0.92 0.841–1.007 0.058
Treatment    0.035    0.026
A1 Reference Reference
A2 0.48 0.35
B1 2.61×10−11 1.92×10−11
B2 0.016 0.013
Intratumoral CD4 1.008 0.997–1.019 0.009    
Stromal CD4     1.0023 1.0002–1.0044 0.0057
  1. A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, CI confidence interval, HR hazard ratio, Dose dose of paclitaxel in group A1, eribulin in groups A2, B1 and B2, HRD homologous recombination deficiency, pCR pathological complete response
  2. Statistically significant P values are shown in italics